If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

DAWN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 8.70%

Insider Buying (Last 12 Months): $29,500,005.00

Insider Selling (Last 12 Months): $30,925,582.47

Day One Biopharmaceuticals Insider Trading History Chart

Day One Biopharmaceuticals Share Price & Price History

^$16.42

▼ -0.27 (-1.62%)

As of 03/23/2023 01:00 AM ET

Days: 30 | 90 | 365

Big Potential, Tiny Penny Stock

From Health Sector Insight | Ad

Little-known stock ready to disrupt the $4.37 trillion wellness market

Click here to download the full report.

Day One Biopharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/10/2023	Samuel C. Blackman	Insider	Sell	10,000	$18.05	$180,500.00	1,233,660
3/7/2023	Jeremy Bender	CEO	Sell	12,500	$20.01	$250,125.00	1,174,276
2/16/2023	Charles N York II	CFO	Sell	930	$19.57	$18,200.10	271,505
2/16/2023	Jeremy Bender	CEO	Sell	3,022	$19.57	$59,140.54	1,186,776
2/16/2023	Samuel C. Blackman	Insider	Sell	674	$19.57	$13,190.18	1,243,660
2/10/2023	Samuel C. Blackman	Insider	Sell	10,000	$20.07	$200,700.00	1,241,710
1/23/2023	Jeremy Bender	CEO	Sell	12,500	$22.00	$275,000.00	1,181,486
1/20/2023	Charles N York II	CFO	Sell	10,000	$22.75	$227,500.00	268,810
1/10/2023	Samuel C. Blackman	Insider	Sell	10,000	$22.86	$228,600.00	1,250,148
1/3/2023	Julie Papanek Grant	Director	Sell	25,000	$20.65	$516,250.00	380,000
12/21/2022	Jeremy Bender	CEO	Sell	12,500	$20.32	$254,000.00	1,192,424
12/20/2022	Charles N York II	CFO	Sell	10,000	$20.07	$200,700.00	276,497
12/8/2022	Julie Papanek Grant	Director	Sell	4,358	$22.08	$96,224.64	405,000
12/1/2022	Julie Papanek Grant	Director	Sell	5,000	$21.75	$108,750.00	414,358
12/1/2022	Samuel C. Blackman	Insider	Sell	10,000	$21.45	$214,500.00	1,260,148
11/21/2022	Charles N York II	CFO	Sell	10,000	$20.76	$207,600.00	286,497
11/21/2022	Jeremy Bender	CEO	Sell	12,500	$20.76	$259,500.00	1,204,924
11/16/2022	Charles N York II	CFO	Sell	430	$21.46	$9,227.80	296,497
11/16/2022	Jeremy Bender	CEO	Sell	1,513	$21.46	$32,468.98	1,217,424
11/16/2022	Samuel C. Blackman	Insider	Sell	377	$21.46	$8,090.42	1,270,148
11/1/2022	Charles N York II	CFO	Sell	10,000	$20.03	$200,300.00	294,401
11/1/2022	Jeremy Bender	CEO	Sell	12,500	$20.03	$250,375.00	1,215,375
11/1/2022	Julie Papanek Grant	Director	Sell	5,000	$20.04	$100,200.00	424,358
10/3/2022	Charles N York II	CFO	Sell	10,000	$20.05	$200,500.00	304,401
10/3/2022	Jeremy Bender	CEO	Sell	12,500	$20.05	$250,625.00	1,227,875
10/3/2022	Julie Papanek Grant	Director	Sell	5,000	$20.06	$100,300.00	434,358
9/21/2022	Julie Papanek Grant	Director	Sell	613,603	$18.55	$11,382,335.65	8,464,301
9/20/2022	Xi L.P. Canaan	Major Shareholder	Sell	148,670	$19.51	$2,900,551.70	9,077,904
9/19/2022	Julie Papanek Grant	Director	Sell	76,725	$20.57	$1,578,233.25	9,226,574
9/16/2022	Xi L.P. Canaan	Major Shareholder	Sell	115,307	$21.55	$2,484,865.85	9,303,299
9/15/2022	Julie Papanek Grant	Director	Sell	51,281	$22.85	$1,171,770.85	9,418,606
9/14/2022	Xi L.P. Canaan	Major Shareholder	Sell	106,111	$23.68	$2,512,708.48	9,469,887
9/13/2022	Julie Papanek Grant	Director	Sell	87,647	$24.40	$2,138,586.80	9,575,998
9/2/2022	Papanek Julie Grant	Director	Sell	5,000	$23.82	$119,100.00	439,358
8/16/2022	Charles N York II	CFO	Sell	1,089	$24.31	$26,473.59	324,401
8/16/2022	Jeremy Bender	CEO	Sell	4,003	$24.31	$97,312.93	1,252,875
8/16/2022	Samuel C. Blackman	Insider	Sell	941	$24.31	$22,875.71	1,299,338
8/4/2022	Charles N York II	CFO	Sell	10,000	$20.05	$200,500.00	321,365
8/4/2022	Jeremy Bender	CEO	Sell	12,500	$20.00	$250,000.00	1,246,192
8/4/2022	Papanek Julie Grant	Director	Sell	5,000	$20.00	$100,000.00	454,358
8/1/2022	Samuel C. Blackman	Insider	Sell	10,000	$16.88	$168,800.00	1,296,718
7/18/2022	Charles N York II	CFO	Sell	2,500	$20.00	$50,000.00	331,365
7/18/2022	Papanek Julie Grant	Director	Sell	2,600	$20.00	$52,000.00	459,358
7/8/2022	Charles N York II	CFO	Sell	1,416	$20.00	$28,320.00	333,865
7/8/2022	Jeremy Bender	CEO	Sell	1,795	$20.00	$35,900.00	1,261,292
7/8/2022	Papanek Julie Grant	Director	Sell	1,242	$20.00	$24,840.00	461,958
7/5/2022	Charles N York II	CFO	Sell	800	$20.00	$16,000.00	335,281
7/5/2022	Jeremy Bender	CEO	Sell	857	$20.00	$17,140.00	1,263,087
7/1/2022	Charles N York II	CFO	Sell	1,479	$20.00	$29,580.00	336,081
7/1/2022	Jeremy Bender	CEO	Sell	1,746	$20.00	$34,920.00	1,263,944
7/1/2022	Papanek Julie Grant	Director	Sell	1,000	$20.00	$20,000.00	464,000
7/1/2022	Samuel C. Blackman	Insider	Sell	10,000	$18.72	$187,200.00	1,306,718
6/17/2022	Ai Day1 Llc	Major Shareholder	Buy	1,200,000	$15.00	$18,000,000.00	10,684,638
6/17/2022	Michael Gladstone	Director	Buy	766,667	$15.00	$11,500,005.00	766,667
6/15/2022	Samuel C. Blackman	Insider	Sell	50,000	$16.26	$813,000.00	1,316,718
1/20/2022	Ai Day1 Llc	Major Shareholder	Buy	4,615	$14.73	$67,978.95
1/18/2022	Ai Day1 Llc	Major Shareholder	Buy	43,429	$14.26	$619,297.54
1/3/2022	Samuel C. Blackman	Insider	Sell	10,000	$17.10	$171,000.00
12/8/2021	Pharmaceutical Co Ltd Takeda	Major Shareholder	Sell	110,338	$18.03	$1,989,394.14
12/6/2021	Pharmaceutical Co Ltd Takeda	Major Shareholder	Sell	97,692	$18.05	$1,763,340.60
12/3/2021	Pharmaceutical Co Ltd Takeda	Major Shareholder	Sell	12,517	$18.47	$231,188.99
12/1/2021	Samuel C. Blackman	Insider	Sell	10,000	$17.22	$172,200.00

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

SEC Filings (Institutional Ownership Changes) for Day One Biopharmaceuticals (NASDAQ:DAWN)

86.08% of Day One Biopharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Day One Biopharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/16/2023	Alliancebernstein L.P.	41,900	$0.90M	0.0%	+10.3%	0.057%
2/15/2023	Schonfeld Strategic Advisors LLC	115,500	$2.49M	0.0%	+393.9%	0.157%
2/15/2023	Squarepoint Ops LLC	30,816	$0.66M	0.0%	N/A	0.042%
2/15/2023	Laurion Capital Management LP	15,000	$0.32M	0.0%	+5.4%	0.020%
2/15/2023	Morgan Stanley	87,265	$1.88M	0.0%	-18.8%	0.119%
2/15/2023	Norges Bank	108,000	$2.32M	0.0%	N/A	0.147%
2/15/2023	E Fund Management Co. Ltd.	10,764	$0.23M	0.0%	N/A	0.015%
2/15/2023	Alps Advisors Inc.	49,856	$1.07M	0.0%	+24.2%	0.068%
2/15/2023	AQR Capital Management LLC	9,511	$0.21M	0.0%	N/A	0.013%
2/15/2023	Atlas Venture Life Science Advisors LLC	7,568,317	$162.87M	19.6%	-7.4%	10.290%
2/15/2023	Braidwell LP	1,246,539	$26.83M	0.9%	N/A	1.695%
2/14/2023	Point72 Asset Management L.P.	461,631	$9.93M	0.0%	N/A	0.628%
2/14/2023	Alyeska Investment Group L.P.	143,218	$3.08M	0.0%	+0.8%	0.195%
2/14/2023	Price T Rowe Associates Inc. MD	2,182,578	$46.97M	0.0%	+4.2%	2.967%
2/14/2023	Parkwood LLC	19,353	$0.42M	0.1%	+4.8%	0.026%
2/14/2023	Driehaus Capital Management LLC	483,484	$10.41M	0.2%	-1.3%	0.657%
2/13/2023	Charles Schwab Investment Management Inc.	203,905	$4.39M	0.0%	+2.5%	0.277%
2/13/2023	Deutsche Bank AG	16,810	$0.36M	0.0%	+44.9%	0.023%
2/13/2023	Barclays PLC	109,552	$2.36M	0.0%	+21.1%	0.149%
2/13/2023	Renaissance Technologies LLC	147,426	$3.17M	0.0%	+50.6%	0.200%
2/13/2023	The Manufacturers Life Insurance Company	59,154	$1.26M	0.0%	+3.0%	0.080%
2/13/2023	ExodusPoint Capital Management LP	65,929	$1.42M	0.0%	+411.0%	0.090%
2/13/2023	Martingale Asset Management L P	32,042	$0.69M	0.0%	N/A	0.044%
2/13/2023	Geode Capital Management LLC	580,484	$12.49M	0.0%	+4.7%	0.789%
2/13/2023	JPMorgan Chase & Co.	72,006	$1.55M	0.0%	-6.9%	0.098%
2/13/2023	Penn Mutual Asset Management LLC	24,920	$0.54M	0.6%	N/A	0.034%
2/10/2023	Bank of America Corp DE	124,473	$2.68M	0.0%	-20.3%	0.169%
2/10/2023	Franklin Resources Inc.	2,472,849	$53.22M	0.0%	-0.2%	3.362%
2/10/2023	Cheyne Capital Management UK LLP	27,223	$0.59M	1.0%	N/A	0.037%
2/10/2023	Lord Abbett & CO. LLC	506,178	$10.89M	0.0%	+0.4%	0.688%
2/10/2023	Pathway Capital Management LP	995,686	$21.43M	38.2%	+147.0%	1.354%
2/9/2023	Mirae Asset Global Investments Co. Ltd.	15,292	$0.33M	0.0%	+28.0%	0.021%
2/9/2023	Dimensional Fund Advisors LP	138,608	$2.98M	0.0%	+169.6%	0.188%
2/9/2023	Principal Financial Group Inc.	13,028	$0.28M	0.0%	N/A	0.018%
2/9/2023	Citigroup Inc.	90,013	$1.94M	0.0%	-31.7%	0.122%
2/8/2023	UBS Group AG	129,857	$2.80M	0.0%	+501.0%	0.177%
2/7/2023	State Board of Administration of Florida Retirement System	10,650	$0.23M	0.0%	-22.6%	0.014%
2/3/2023	Fisher Asset Management LLC	36,226	$0.78M	0.0%	-20.4%	0.049%
2/2/2023	SG Americas Securities LLC	13,139	$0.28M	0.0%	+36.6%	0.018%
2/2/2023	ProShare Advisors LLC	9,645	$0.21M	0.0%	N/A	0.013%
2/1/2023	Canaan Partners XI LLC	2,548,403	$54.84M	43.1%	-63.4%	3.465%
2/1/2023	Legato Capital Management LLC	23,774	$0.51M	0.1%	N/A	0.032%
12/8/2022	Bank of New York Mellon Corp	102,223	$2.05M	0.0%	+60.9%	0.139%
11/21/2022	California State Teachers Retirement System	10,929	$0.22M	0.0%	+9.5%	0.015%
11/15/2022	Alliancebernstein L.P.	38,000	$0.76M	0.0%	-10.4%	0.052%
11/15/2022	State Street Corp	2,041,738	$40.90M	0.0%	+469.1%	2.776%
11/15/2022	Tang Capital Management LLC	400,000	$8.01M	1.0%	N/A	0.544%
11/15/2022	Vanguard Group Inc.	2,615,441	$52.39M	0.0%	-0.4%	3.556%
11/15/2022	Price T Rowe Associates Inc. MD	2,094,913	$41.96M	0.0%	+2.6%	2.848%
11/15/2022	Parkman Healthcare Partners LLC	212,191	$4.25M	1.2%	+84.9%	0.288%
11/15/2022	Lord Abbett & CO. LLC	504,251	$10.10M	0.0%	N/A	0.686%
11/15/2022	Laurion Capital Management LP	14,237	$0.29M	0.0%	-5.1%	0.019%
11/15/2022	Bank of New York Mellon Corp	102,223	$2.05M	0.0%	+60.9%	0.139%
11/15/2022	Bayesian Capital Management LP	13,508	$0.27M	0.1%	N/A	0.018%
11/15/2022	BlackRock Inc.	2,541,235	$50.90M	0.0%	+29.5%	3.455%
11/14/2022	Tudor Investment Corp Et Al	36,544	$0.73M	0.0%	N/A	0.050%
11/14/2022	Cubist Systematic Strategies LLC	125,586	$2.52M	0.0%	+105.1%	0.171%
11/14/2022	Renaissance Technologies LLC	97,900	$1.96M	0.0%	-16.1%	0.133%
11/14/2022	Nuveen Asset Management LLC	448,770	$2.97M	0.0%	+518.5%	0.610%
11/14/2022	Parkwood LLC	18,475	$0.37M	0.1%	N/A	0.025%
11/14/2022	Healthcare of Ontario Pension Plan Trust Fund	54,000	$1.08M	0.0%	N/A	0.073%
11/10/2022	ExodusPoint Capital Management LP	12,903	$0.26M	0.0%	-43.9%	0.018%
11/10/2022	Dimensional Fund Advisors LP	51,408	$1.03M	0.0%	N/A	0.070%
11/10/2022	Tower Research Capital LLC TRC	2,186	$44K	0.0%	-41.7%	0.003%
11/10/2022	UBS Group AG	21,606	$0.43M	0.0%	+461.0%	0.029%
11/9/2022	Amalgamated Bank	3,577	$72K	0.0%	+21.0%	0.005%
11/9/2022	Atlas Venture Life Science Advisors LLC	8,169,171	$163.63M	18.1%	-8.9%	11.120%
11/8/2022	Fisher Asset Management LLC	45,526	$0.91M	0.0%	N/A	0.062%
11/8/2022	New York State Common Retirement Fund	51,790	$1.04M	0.0%	+166.0%	0.071%
11/4/2022	Prudential Financial Inc.	38,315	$0.77M	0.0%	N/A	0.052%
11/3/2022	Barclays PLC	90,429	$1.81M	0.0%	+7,615.8%	0.123%
11/2/2022	Summit Rock Advisors LP	25,751	$0.52M	0.4%	-22.3%	0.035%
10/31/2022	Canaan Partners XI LLC	6,964,301	$139.50M	56.3%	-27.9%	9.480%
8/22/2022	ExodusPoint Capital Management LP	23,003	$0.41M	0.0%	N/A	0.031%
8/18/2022	Goldman Sachs Group Inc.	1,894,537	$33.91M	0.0%	+5,969.9%	2.579%
8/17/2022	Macquarie Group Ltd.	110,000	$1.97M	0.0%	N/A	0.150%
8/16/2022	Utah Retirement Systems	34,184	$0.61M	0.0%	-15.7%	0.047%
8/16/2022	Woodline Partners LP	150,176	$2.69M	0.0%	N/A	0.204%
8/16/2022	Price T Rowe Associates Inc. MD	2,041,344	$36.54M	0.0%	+28.7%	2.779%
8/16/2022	Commodore Capital LP	739,661	$13.24M	2.8%	N/A	1.007%
8/16/2022	Deerfield Management Company L.P. Series C	3,512,123	$62.87M	1.3%	+68.3%	4.781%
8/16/2022	Driehaus Capital Management LLC	501,689	$8.98M	0.1%	+24.3%	0.683%
8/15/2022	Occudo Quantitative Strategies LP	23,619	$0.42M	0.0%	N/A	0.032%
8/15/2022	State Street Corp	358,783	$6.42M	0.0%	+65.9%	0.488%
8/15/2022	Macquarie Group Ltd.	110,000	$1.97M	0.0%	N/A	0.150%
8/15/2022	Cubist Systematic Strategies LLC	61,237	$1.10M	0.0%	N/A	0.083%
8/15/2022	Laurion Capital Management LP	15,000	$0.27M	0.0%	-83.6%	0.020%
8/15/2022	Millennium Management LLC	17,555	$0.31M	0.0%	-90.0%	0.024%
8/13/2022	Quantbot Technologies LP	2,900	$51K	0.0%	N/A	0.004%
8/13/2022	Renaissance Technologies LLC	116,630	$2.09M	0.0%	N/A	0.159%
8/12/2022	Northern Trust Corp	190,510	$3.41M	0.0%	+11.9%	0.259%
8/12/2022	Virtus ETF Advisers LLC	6,551	$0.12M	0.0%	-26.3%	0.009%
8/12/2022	FMR LLC	6,826,574	$122.20M	0.0%	+163.1%	9.293%
8/12/2022	Franklin Resources Inc.	2,465,380	$44.13M	0.0%	+59.8%	3.356%
8/12/2022	Rhumbline Advisers	33,954	$0.61M	0.0%	+74.9%	0.046%
8/11/2022	UBS Group AG	3,851	$69K	0.0%	N/A	0.005%
8/11/2022	Alps Advisors Inc.	36,730	$0.66M	0.0%	-42.3%	0.050%
8/5/2022	State Board of Administration of Florida Retirement System	13,760	$0.25M	0.0%	N/A	0.019%
8/4/2022	TD Asset Management Inc.	46,333	$0.83M	0.0%	+23.7%	0.063%
8/3/2022	Atlas Venture Life Science Advisors LLC	8,968,305	$160.53M	26.8%	+9.3%	12.217%

Data available starting January 2016

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Today's Range

Now: $16.42

$16.26

$16.93

50 Day Range

MA: $19.98

$16.42

$23.41

52 Week Range

Now: $16.42

$5.44

$28.35

Volume

455,105 shs

Average Volume

480,808 shs

Market Capitalization

$1.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Day One Biopharmaceuticals?: Day One Biopharmaceuticals' top insider investors include:
Ai Day1 Llc (Major Shareholder)
Julie Papanek Grant (Director)
Xi LP Canaan (Major Shareholder)
Samuel C Blackman (Insider)
Jeremy Bender (CEO)
Michael Gladstone (Director)
Papanek Julie Grant (Director)
Charles N York II (CFO)
Pharmaceutical Co Ltd Takeda (Major Shareholder)
Venture Fund Xi LP Atlas (Major Shareholder)
Learn More about top insider investors at Day One Biopharmaceuticals.
Who are the major institutional investors of Day One Biopharmaceuticals?: Day One Biopharmaceuticals' top institutional shareholders include:
Atlas Venture Life Science Advisors LLC — 10.29%
Canaan Partners XI LLC — 3.46%
Franklin Resources Inc. — 3.36%
Price T Rowe Associates Inc. MD — 2.97%
Braidwell LP — 1.69%
Pathway Capital Management LP — 1.35%
Learn More about top institutional investors of Day One Biopharmaceuticals stock.
Which major investors are selling Day One Biopharmaceuticals stock?: During the previous quarter, DAWN stock was sold by these institutional investors:
Canaan Partners XI LLC
Atlas Venture Life Science Advisors LLC
Citigroup Inc.
Bank of America Corp DE
Morgan Stanley
Fisher Asset Management LLC
Driehaus Capital Management LLC
JPMorgan Chase & Co.
During the previous year, company insiders that have sold Day One Biopharmaceuticals company stock include:
Ai Day1 Llc (Major Shareholder)
Julie Papanek Grant (Director)
Xi LP Canaan (Major Shareholder)
Samuel C Blackman (Insider)
Jeremy Bender (CEO)
Michael Gladstone (Director)
Learn More investors selling Day One Biopharmaceuticals stock.
Which major investors are buying Day One Biopharmaceuticals stock?: Within the previous quarter, DAWN stock was acquired by institutional investors including:
Braidwell LP
Pathway Capital Management LP
Point72 Asset Management L.P.
UBS Group AG
Norges Bank
Schonfeld Strategic Advisors LLC
Price T Rowe Associates Inc. MD
Dimensional Fund Advisors LP
Within the previous year, these company insiders have bought Day One Biopharmaceuticals stock:
Ai Day1 Llc (Major Shareholder)
Julie Papanek Grant (Director)
Xi LP Canaan (Major Shareholder)
Samuel C Blackman (Insider)
Learn More investors buying Day One Biopharmaceuticals stock.